
PHAXIAM

PHAXIAM

Building a Global Leader in AMR Infections Therapies

May 2024

- This document has been prepared by PHAXIAM (the "Company") and is provided for information purposes only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris and Nasdaq. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness.
- This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of the Company in any jurisdiction.
- The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.
- The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accepts no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.
- This document contains information on the Company's markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information.
- This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.
- Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures, amounts or percentages.
- All persons accessing this document must agree to the restrictions and limitations set out above.

Agenda

1. Global Context
2. PHAXIAM Differentiation
3. Development Strategy
4. Communication & Financing

The Antimicrobial Resistance (AMR)



Uncontrolled resistance to antibiotics despite several generations of active compounds

There is a CRITICAL NEED to address Antimicrobial Resistance

Phage Therapy, a Solution for Resistant Infections



Bacteriophages: viruses, natural predators of bacteria



Unique mode of action

- **Specificity**
- **Speed** (less than 45 min)
- **Self-replication** down to the last bacterium

Phage Therapy allows SIMPLE, EFFECTIVE and WELL-TOLERATED treatments

The Strong Momentum of Phage Therapy

INCREASING IMPACT of difficult-to-treat resistant infections Rising concern among public authorities and medical community	→ CRITICAL NEEDS FOR ALTERNATIVE TECHNOLOGIES
High safety and promising clinical benefits from REAL-LIFE treatments Increased probability of success from early clinical evidence	→ PROMISING REAL-LIFE CLINICAL DATA
Active collaboration with REGULATORY AGENCIES Strong support / Clear development guidelines / Accelerated paths	→ ATTRACTIVE REGULATORY CONTEXT
GMP STANDARDIZATION & CMC developments Robust GMP processes / Well characterized phages	→ MATURITY OF THE TECHNOLOGY
Better understanding of resistance mechanisms NEW TOOLS to address potential emergence of phage resistance	→ SOLUTIONS TO POTENTIAL RESISTANCE

Phage Therapy is a TOP-10 INNOVATION to be developed according to the 2023 World Economic Forum

Reinforced interest in Phage Therapy

Major Commitment from Top Tier US investors in March 2024



Purchase agreement with a $50M financing led by Top tier investor base, incl. Deerfield and Orbimed

Armata Pharmaceuticals has recently announced a $35M refinancing with Innoviva

Growing attractiveness of the phage-therapy field to leading investors

Competitive Landscape



PHAXIAM is the EUROPEAN LEADER in Phage Technology
Direct major Competitors are US-based
Very Recent Merger between BiomX & APT

Key Technology Assets for PHAXIAM Treatments

1 **SELECT phages to maximize breadth of repertoire**

Internal PHAXIAM Technology and Expertise



2 **PRODUCE large scale GMP batches of high purity**

Internal PHAXIAM process development Capabilities and Expertise

Industrial partnership to produce "off-the-shelf" GMP-grade phages

3 **TEST PHAGOGRAM for a precision therapy**

PHAXIAM proprietary IVD Test

4 **DISTRIBUTE personalized therapeutics to patients' bed**

Supply chain in place with a few days leadtime

Discovery, Screening, Characterization, GMP production, Testing, Distributing

Real-life Clinical Data From ~100 Treated Patients

- STRONG SUPPORT from Regulatory Authorities & >15 hospitals
- SEVERAL ROUTES OF ADMINISTRATION TESTED, including local, intravenous, nebulisation, …
- 7 DIFFERENT INDICATIONS TREATED with a majority of PJI





PROMISING CLINICAL ACTIVITY RESULTS

(First 77 patients evaluated)
2020-2024

- EXCELLENT RESULTS observed in reported cases: safety + clinical benefit
- Several PUBLICATIONS

~ 80% CONTROL RATE of infection @3months for PJI Patients (n=42)

VERY PROMISING Data in « hard to treat » population

(very severe infections - 2nd/3rd line antibiotics)

AAC* Regulatory Status from French Authority (June 2022)

ansm
Agence nationale de sécurité du médicament et des produits de santé

COMPASSIONATE ACCESS AUTHORIZATION (AAC)

SOURCE OF REVENUES

To be extended to OTHER AAC* INDICATIONS

Process towards an EARLY ACCESS AUTHORIZATION

To be extended to ORPHAN STATUS

An Important First Step for MARKET ACCESS in EUROPE

Corporate Strategy

POSITION THE COMPANY AS A GLOBAL LEADER

1. EXPAND CLINICAL PORTFOLIO IN HIGH-VALUE INDICATIONS
2. INTENSIFY BD ACTIVITIES & ANTICIPATE MARKET ACCESS
3. IMPLEMENT GLOBAL MANUFACTURING
4. BOOST R&D CAPABILITIES & EXPAND PHAGE PLATFORM

PHAXIAM

An Ambitious Clinical Development Strategy

Target High-Value Indications

Severe Resistant Infections with High unmet medical needs

high mortality rate / high budget impacts → claim high pricing

Accelerate the Path to Global Registration

Launch the 1st global randomized Phase 2 study at international scale in PJI*

Leverage on potential Early access pathway (after Phase 2)

Diversify Portfolio

Target several Life-Threatening Infections (Endocarditis, VAP**, …)

Target several Virulent & Resistant Bacteria (E. *coli*, P. *aeruginosa*, …)

* Prosthetic Joint Infections

**Ventilated-acquired Pneumopathies

A Balanced Clinical Portfolio



PJI, a strategic indication for PHAXIAM

- Relatively High incidence: ~50-60K PJI* (US/EU5; 2027)
- Very High economic burden (cost ~ $150K in US, €50-70K in EU) → high price

- Most advanced player in EU and US (APT stopped, Armata 18 months behind)
- Clear leadership → 1st to Market

1 **Attractive indication**

2 **High unmet medical need**

PJI* Strategic indication

3 **Strong competitive position**

4 **Highest probability of robust POC for Phages**

- Rare & devastating complication
- 50% failure rate with DAIR**
- High risk of re-infection (60%), amputation (~11%), mortality (25% at 5 years)

- Derisked by Real-life Compassionate experience
- Local route of administration

Unique and leadership position in the strategic PJI indication

PHAXIAM

** Prosthetic Joint Infection (PJI)*
*** SOC = Debridement, Antibiotic, Implant Retention*

First Global (EU/US) PJI Phase 2 Study (GLORIA)

Global Integrated Phase 2 Proof of Concept Study
Multicentric, Randomized
to assess the Efficacy & Safety
of Phage Therapy in Patients (n=100) with Hip or Knee PJI
with open-surgery debridement (DAIR) in combination with antibiotics

Expected Launch (FPI) Q1 2025

1. **High-Value Indication toward Registration**
2. **Interactions with EMA SA & FDA Pre-IND**
3. **Real-Life Data Available on Safety & Efficacy** (~100 patients treated)
4. **Supportive Clinical Data Coming in 2024** (PhagoDAIR)
5. **Large Patients Population** (x5-6 vs. PhagoDAIR)

Preparation of the GLORIA study

- Positive and consistent feedback from the FDA (pre-IND meeting) and EMA (scientific advice)
- Regulatory filings expected in the US and EU (July/August), then in the UK (September) → Approval expected in Q4 2024
- Global CRO selection in final steps
- Sites selection ongoing: ~40 sites and countries (FR, ESP, GER, NLD, ITA, UK, US)
- Launch of the clinical study in Q1 2025, clinical results expected in H2 2026

Progress in line with our objectives

Expected Major Clinical Catalysts

Financial Position

Cash position as of March, 2024: €5.8m

Cash Runway into August 2024

Reviewing options to further extend cash Runway

Key Messages

Concern is growing about **AMR Infections**, the "New Global Pandemics"
Phage Therapy is the Therapeutic Solution for Multi-resistant Bacterial Infections

- A new momentum for Phagotherapy with **an increased interest from financial investors**
- Ambitious strategy by focusing on High-Value Indications targeting **Life-Saving Therapeutics** according to Pharma standards
- De-risked **Clinical Strategy with real-life demonstrated Clinical Efficacy and Safety**
- **Performing Sales, First-to-Market** anticipating Market access in 2027 (Early Access Pathway)
- Secured and in place GMP-**Manufacturing** (Pharma standards) **& Logistics Capabilities**
- **Environmental-friendly technology**
- Robust execution Capabilities

Thanks | PHAXIAM

Experienced & Complementary Leadership Team

Thibaut du Fayet
CEO

Eric Soyer
COO CFO

Pascal Birman, MD
CMO

Jérôme Bailly
CQO / CTO

Cindy Fevre
CSO

Karine Charton
CBO

Frédérique Vieville
CRO

Anne-Cécile Fumey
VP HR

Pherecydes and Erytech merged to build PHAXIAM

Leveraging on Complementary Capabilities from both Executive Teams

Leading Phage Therapy Platform

Leading Edge in Clinical Development

Regular Interactions with Regulatory Agencies & HTA agencies

Strong internal R&D, CMC & GMP Capabilities

Proprietary PHAGOGRAM® IVD Solution

Large Phage Bank for the most critical bacterial Infections

Strong IP with 87 patents filed

PHAXIAM

Developments within a regulatory framework validated by key health authorities

ansm

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

FDA
U.S Food and Drug Administration

Network of prestigious scientific partners

Institut Pasteur

Crioac GSO

INRA
SCIENCE & IMPACT

BIOASTER
MICROBIOLOGY TECHNOLOGY INSTITUTE

Manufacturing & Logistics strategic capabilities

In-house process development & analytical science

In-house highly purified phages manufacturing

Strategic partnership with MB Pharma (CMO, EU) to manufacture GMP bacteriophages clinical batches

Pharmaceutical supply chain mastered to ensure robust and short lead time clinical supply (clinical studies, AAC, ….)

Major achievements

- > 35 GMP clinical batches produced
- Low Manufacturing COGS
- Available capacity till early market launch
- Short supply lead time (> 1 week)



Manufacturing & Logistics Capacities Fit to Address future Clinical Demand

PHAXIAM, a new company

erytech

HQ in Lyon, Office in Boston

Listed on Euronext, Nasdaq ERYP LISTED EURONEXT Nasdaq

- Leader in red blood cell-based therapeutics
- Late-stage clinical experience in oncology
- Phase 3 trial in second-line pancreatic cancer did not meet its primary endpoint (Q4 2021), following which Erytech:
  - Launched strategic partnering process
  - Sold its US manufacturing facility
  - Restructured, keeping core R&D, QA and support teams
  - Focused preclinical programs on promise of extracellular vesicles (EV) for drug delivery

PHERECYDES PHARMA

HQ in Nantes, Office in Paris

Listed on Euronext Growth ALPHE EURONEXT GROWTH

- Leading European player in phage therapy against resistant bacterial infections, a major global health issue
- Phase 2 trial ongoing: enrolment on track, data expected Q1 2024
- > 65 patients already benefited from compassionate treatments with
  - Systematic & strong support of the Health Authorities
  - Encouraging clinical efficacy and tolerability observed in reported cases to date
- Large & robust IP portfolio
- Ambitious development strategy

Many synergies to leverage

erytech PHERECYDES PHARMA

Experienced in late-stage clinical development

RDD & Manufacturing capabilities (proteins engineering)

US presence & experience

Nasdaq / Euronext dual listing



Ongoing Ph2 PJI trial & established clinical development plan

Phage RD & manufacturing capabilities

Initiation of partnership discussions

- Development beyond ID Human Health: one health, cosmetics
- Phagogram IVD solution

Targeting High-value Resistant Infections

Life-Threatening Conditions

Potential Orphan Status Indications

The most severe Hospital-Acquired and Resistant Infections



Additional Clinical Studies

TRIALS	STATUS AND PROGRESS
Endocarditis Infections (EI) **Staph. aureus** **Phase I PK**	**Demonstration for IV indications before Registration Study** • Resistant infections in cardiac chambers and valves • IV-administered Phages Key milestones : First Patient-In, April 2024
Complex Urinary Tract Infections (cUTI) **E. coli** **Phase I PK**	**Demonstration for intra-bladder administration before Registration Study** • cUTI with resistant E. Coli infections in the bladder • Phages administered locally into the bladder Key milestones : ANSM study validation in April 2024